

NRG-CC011: A study to examine computerized training to improve concentration, learning new things, and remembering in breast cancer survivors.



Visit the patient
webpage for this
study:



ABOUT THE TRIAL

NRG-CC011 is a clinical study trying to determine if computerized cognitive training can improve cancer-related cognitive impairment including the ability to concentrate, learn new things, remember, and make decisions that affect daily life in breast cancer survivors.

We are doing this study to determine the usefulness of computerized cognitive training for cancer-related cognitive impairment and to compare different approaches to cognitive training.

[ClinicalTrials.gov Identifier NCT05896189](https://clinicaltrials.gov/ct2/show/study/NCT05896189)

This NRG Oncology protocol is being conducted in collaboration with The Ohio State University College of Nursing



ABOUT NRG ONCOLOGY

As one of the five research groups in the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG

Oncology's extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI.



Frequently Asked Questions

What is a clinical trial?

Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?

Stage I-III, non-metastatic breast cancer survivors who are 18 years of age or older and are 6 months to 5 years post-treatment with cancer-related cognitive impairment (CRCI) are eligible to participate in the NRG-CC011 study.

Am I required to be in this study?

No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?

If you decide to take part in this study, you will join one of two computerized cognitive training groups. Whichever group you are assigned to you will be asked to complete activities that will require you to attend to, learn, process and remember information.

How long will I be in this study?

There are three tasks (computerized cognitive training, participant-completed survey questionnaires and the cognitive telephone assessments) that you will be asked to complete throughout the study. As part of the cognitive training, you will complete up to 40 hours of the assigned activity over a 10-week period for an average of approximately 4 hours per week based on your schedule. Research staff from The Ohio State University will contact you via phone or email to find a convenient time to get you started on the program you are assigned. You will complete survey questionnaires and complete cognitive telephone assessments at baseline (prior to cognitive training) and at 12, 24, and 36 weeks after joining the study. Thus, overall your participation in this study will last about 9 months.

Are there side effects?

There is a risk that you may feel uncomfortable answering some of the questions asked or completing the cognitive assessment in this study.

MORE INFORMATION

Visit the National Cancer Institute website at <https://www.cancer.gov> for more information about studies or general information about cancer.

You may also call: 1-(800)-4-CANCER (1-800-422-6237).